The finding that LGP2 was required for the increase in NF-κB activity induced by DDX39B loss demonstrates a mechanism by which these RNA helicases may interact to regulate response to therapy and indicate that modulating DDX39B or its interaction with LGP2 represents a strategy to improve the response to cancer chemotherapy. The gene discussed is DDX39B; the disease is cancer.